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trolled trials (RCTs) evaluating Dabigatran for the treatment of AF. We included stud-
ies that were: (1) a RCT in humans; (2) an investigation of patients with nonvalvular 
atrial fibrillation; (3) an evaluation of dabigatran compared with warfarin or each 
other; and (4) a report of results of stroke or systemic emboli and major bleeding. A 
systematic literature search for dabigatran trials was undertaken for the databases 
Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the 
study size, interventions, year and total bleeding events. For meta-analysis, random 
effects and fixed effects models were used to obtain cumulative statistics. Results: 
Two RCTs with a total of 12,268 patients were identified. The pooled event rate 
for Dabigatran for total bleeding events was 31.9% (95% CI 31%-33%). The pooled 
response rate for Warfarin for total bleeding events was 35.1% (95% CI 34%-37%). The 
cumulative relative risk for total bleeding events with Dabigatran versus Warfarin 
was 0.91 (95% CI 0.89-0.93). ConClusions: Meta-analysis shows Dabigatran has a 
slightly lower rate of total bleeding events compared to Warfarin.
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objeCtives: The objective of the study was to determine costs and clinical out-
comes of antihypertensive treatment patients taking amlodipine or telmisar-
tan. Methods: This year long prospective observational study was carried out 
at cardiology OPD of a private tertiary health care hospital. The patients over 20 
years of age, either sex, with clinically diagnosed hypertension (JNC VII) receiving 
either telmisartan (40 & 80 mg OD) or amlodipine (5 mg OD or BD) were followed for 
a period of at least 8 weeks after baseline assessment. An attempt made to under-
stand the direct costs involved. The primary outcome measured was difference in 
SBP and DBP after 8 weeks of treatment vs. baseline BP. Only the direct costs were 
included. Results: Of 250 patients studied, 120 belonged to the amlodipine and 
130 to the telmisartan group. 150 had a family history of hypertension. The aver-
age systolic and diastolic BP was 153.90±15.7 and 93.36±7.1 mmHg, respectively. 
Age, weight, height, BMI, Baseline SBP and DBP and duration of hypertension did 
not differ in between amlodipine and telmisartan group. The prevalence of CAD 
was more in male patients; and, the prevalence of diabetes was more in female 
patients. The average reduction in SBP was amlodipine and telmisartan group 
was 17.92±10.2mmHg and 18.48±13.6 mmHg. The average DBP reduction found in 
amlodipine and telmisartan group were 9.45±7.3 and 10.3±6.9 mmHg. However, 
at the end of the minimal follow up period, there was no statistically significant 
difference found in reduction of DBP. BP control was significantly different in 
diabetic and non-diabetic patients. The average cost of drugs per mmHg reduction 
of BP was INR973 and INR812 in amlodipine and telmisartan arms, respectively, 
in non-diabetic hypertensive patients on monotherapy. ConClusions: Despite 
its limitations, the results offer indicative evidence using the real-time Asian 
Indian patients.
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objeCtives: Current guidelines recommend a combination of ACEIs/ARBs, beta-
blockers and aldosterone antagonists for the treatment of chronic heart disease; 
however, previous studies have found minimal use of these medications. This 
study aimed to evaluate the physicians’ adherence to treatment guidelines and 
to explore the association between adherence to guidelines and re-hospitalization 
in patients with chronic heart failure in Thailand. Methods: This retrospec-
tive cohort study collected data from systolic heart failure patients who received 
treatment from a tertiary university-affiliated hospital between January 2008 and 
December 2010 and were followed-up for 2 years. The evaluation of the physicians’ 
adherence to treatment guidelines in prescribing ACEIs/ARBs, beta-blockers and 
aldosterone antagonists (primary endpoint) were conducted by using a Guideline 
Adherence Indicator (GAI-3; classified as low, medium and high) according to the 
recommendation of guidelines. The secondary endpoint was re-hospitalization for 
CHF during the follow-up period. Results: Of 155 patients, more patients were 
prescribed beta-blockers (65.8%) than ACEIs/ARBs (50.7%) and aldosterone antag-
onists (20.0%). Twenty-five, 47 and 28 percent of patients were classified as low, 
medium and high GAI-3, respectively. The rate of re-hospitalization was lower in 
patients with a high GAI-3 score compared to patients with a medium or low GAI-3 
score (79.1 vs. 90.4 vs. 94.9, per 100 person-years, respectively). Multivariable Cox 
regression analysis (adjusted by sex, age, NYHA Functional Class and comorbidity) 
found that patients with high and medium GAI-3 scores had a lower risk of re-
hospitalization compared with low GAI-3 score (high GAI-3 score:adjusted HR 0.184, 
95%CI:0.093-0.367,p< 0.001; medium GAI-3 score: adjusted HR 0.436, 95%CI:0.238-
0.797,p= 0.007). ConClusions: Physicians’ adherence to treatment guidelines for 
systolic heart failure was not optimal. Some patients did not receive medications 
following the guidelines’ recommendation. Our results suggested that using medi-
cations following treatment guidelines was an important factor to reduce the risk 
of re-hospitalization from heart failure.
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objeCtives: Warfarin, a widely prescribed oral anticoagulant, is well known to have a 
narrow therapeutic index. Many studies confirmed that adherence helps to achieve a 
stabilization of the INR, but little data is available on the impact of the use of a pillbox. 
The objective of this study is to evaluate the association between the use of a pillbox 
among new warfarin-users and time in therapeutic range (TTR). Methods: This 
study was based on a prospective cohort of new warfarin-users which aims to assess 
the genetic, clinical and environmental risk factors associated with the effectiveness 
and safety of warfarin. Demographic and clinical data were collected among a sub-
group of 702 patients who began the treatment between May 1st, 2010 and Aug. 31st, 
2012 at one of 18 hospitals in Quebec, Canada. Patients were followed-up each three 
months up to a year after the initiation of warfarin. Our outcome was the TTR and 
it was tested using a mixed linear model to allow for repeated measures. Results: 
Mean age was 70.0 ± 11.6, 60.1% were men, 79% had atrial fibrillation as a primary 
indication for warfarin, 67.9% had hypertension and 61.1% had dyslipidemia. Of these 
patients, 47.2%, 53.1%, 56.1% and 60.4% used a pillbox at 3, 6, 9 and 12 months, respec-
tively. Patients who used their own pillbox (approximately 75% of pillbox users) had 
a higher TTR than non-users (3.7%, p= 0.03). These results were adjusted for the INR 
target, age, number of concomitant drugs and patient-reported dose of warfarin as 
these covariates were significantly associated with the outcome. ConClusions: 
There is a significant association between the use of a pillbox prepared by the patient 
and a higher TTR. The use of this device may improve the stability of patients taking 
warfarin, but the clinical significance of this finding is arguable.
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objeCtives: Diuretics are drugs of first choice in the treatment of hypertension. 
The aim of this study was to analyze the consumption of diuretics in Serbia in the 
period from 2008 to 2012 year. Methods: The data about the use of drugs were 
taken from the Agency for Drugs and Medical Devices of the Serbia. Results: The 
use of diuretics during the observed period in Serbia is quite small and it ranged 
from 5 to 6% of the total consumption of all drugs from the C group. Furosemide was 
the most frequently used diuretic from 2008-2010. In the observed period consump-
tion of furosemide ranged about 61 % of the total consumption of all diuretics. On 
the second place in consupmtion during first three years of the study was indapa-
mide. Indapamid records decline in consumption in next two years. In 2011. and 
2012. hydrochlorothiazide takes second place in consumption and marks a possitive 
trend. In 2012. it ranged 7.92 DDD/1000 inh/day. Spironolactone takes the fourth 
position in the first three years. During the 2011. and 2012. consumption of spirono-
lactone has increased and took the third position in consumption. Consumption 
of all other diuretics was small. ConClusions: In Serbia, in the observed period, 
consumption of diuterics were uneven. It is two to three times lower in compari-
son with the consumption of diuretics in Norway and Finland. This research was 
supported by Provincial Secretariat for Science and Technological Development, 
Autonomous Province of Vojvodina project No 114-451-2458/2011 and by Ministry 
of Science, Republic of Serbia, project no 41012.
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objeCtives: Patients with a history of a cardiovascular (CV) disease are at high risk 
of developing secondary major adverse cardiac events (MACE), including death, non-
fatal myocardial infarction (MI), stroke, symptomatic pulmonary embolism, CV and 
all-cause hospitalization, and bleeding. The objective is to review the epidemiology 
and burden of MACE in patients with coronary artery disease (CAD) or peripheral 
arterial disease (PAD) in Europe, Asia, Latin America and Canada. Methods: A 
comprehensive search was conducted in PubMed, EMBASE, Cochrane and other 
relevant sites. 460 full-text articles, published between 2003 and 2013, were 
reviewed. Results: MACE was more prevalent in CAD/PAD patients compared to 
matched controls (> 2-fold higher). Proportions of CAD patients who have had MI, 
stroke, or bleeding were 1.4%–3.0%, 1.24% and 0.81%, respectively. For PAD patients, 
these proportions were 1.37%–13.7%, 0.4%–5.2%, and 1.3%, respectively. Compared 
to individuals with no CV disease, MACE incidence in CAD or PAD patients was 
increased by at least two-fold, ranging from 18.1%–32.3% for all-cause death, 
12.1%–18.9% for CV death, 8.2%–17.3% for MI and 6.8%–11.3% for stroke. In patients 
with CAD, evidence of MACE was reported within 30 days of primary percutane-
ous coronary intervention and incidence increased over time. The main risk fac-
tors for MACE in CAD/PAD patients included increased oxidative stress in coronary 
and peripheral arteries, diabetes, and chronic kidney disease. Limited information 
was found on the economic and humanistic burden of MACE in CAD/PAD patients. 
Available data showed that MACE occurrence increased hospitalization rates and 
associated costs, in addition to worsening patients’ quality of life. ConClusions: 
Although gaps in the literature were identified, this assessment showed that the 
risk of MACE is substantial among CAD/PAD patients and imposes a considerable 
burden. Development of preventive measures is warranted.
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bACkgRound: The rates of cardiovascular (CV) events are highest in the period 
immediately after an initial MI but may remain elevated for an extended period 
of time. objeCtives: Evaluate long-term rates of CV events (recurrent myocar-
dial infarction (MI) and hospitalized stroke) and all cause mortality in patients 
with stable CAD after MI and in patients resembling those of the PEGASUS trial 
(NCT 01225562). Methods: Patients ≥ 50 years old (yo) with an MI followed by ≥ 
12 MI-free months (stable CAD) and no prior stroke were identified from a large 
claims database between 01/2007 and 11/2011. Inclusion and exclusion criteria were 
identified during a 12 month pre-MI baseline. Patients included in the PEGASUS-
like cohort were those having at least one additional risk factor (≥ 1 additional 
prior MI, Age≥ 65, diabetes or chronic non-end-stage renal disease (NESRD)). Rates 
of a composite endpoint (MI or stroke hospitalization or all-cause mortality) in the 
stable CAD and PEGASUS-like populations were estimated during follow-up (up 
to four years) after the stable CAD index. Due to data and population limitations, 
rates were compared in patients < 65 yo only. Results: In the < 65 yo PEGASUS-like 
cohort, 24.4% had ≥ 1 additional prior MI, 76.1% had diabetes, and 27.4% had NESRD. 
Event rates for the PEGASUS-like (n= 5,357) and other stable CAD cohorts (n= 8,135) 
were 60/1,000 and 27/1,000 person-years (py), respectively (p< 0.0001). Hospitalized 
MI was the largest contributor to the composite endpoint (38/1,000 and 19/1,000 
py, respectively, p< 0.0001). Composite event rates in PEGASUS-like patients who 
were still MI-free 2 and 3 years after the index MI were 51/1,000 py and 44/1000 
py, respectively. ConClusions: Stable CAD patients in the US meeting PEGASUS 
clinical trial criteria continue to have an elevated risk of major CV events and all 
cause mortality after several MI-free years.
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objeCtives: Several studies establish that the use of antidepressants associated 
with an increased risk of myocardial infarction (MI). However, available evidence 
on tricyclic antidepressants (TCAs) is conflicting. We therefore examined the 
association between TCAs use and risk of MI by conducting a detailed systematic 
review and meta-analysis using all observational studies published regarding this 
subject. Methods: A PubMed/MEDLINE search was conducted for studies pub-
lished up to 31stDecember, 2013. The studies were first evaluated for publication 
bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence 
intervals (CIs) were calculated using random-effects model if heterogeneity pre-
sents or otherwise fixed-effects model. Cumulative meta-analysis, subgroup and 
sensitivity analyses were also performed. Results: Six (3 cohort and 3 case-
control) studies satisfying the inclusion criteria were considered for this study. 
There was heterogeneity among the studies (pheterogeneity < 0.001, I2 = 98%) but no 
publication bias (Begg’s p = 0.70 and Egger’s p = 0.45). We observed no association 
between TCAs use and risk of MI (RR 1.14, 95% CI 0.67-1.96, p = 0.622). But, the 
sensitivity analysis revealed that the TCAs users are having 36% increased risk of 
MI after excluding one outlier (RR 1.36, 95% CI 1.10-1.67, p < 0.001) with less hetero-
geneity (pheterogeneity = 0.001, I2 = 78%). Subgroup analysis by study design shows 
that case-control studies are having positive association (RR 1.41, 95% CI 1.37-1.45, 
p < 0.001) but, cohort studies having no association (RR 0.94, 95% CI 0.40-2.23, 
p= 0.893) because of an outlier cohort study. Further, cumulative meta-analysis 
showed a change in trend of reporting MI risk from positive to no association in 
TCAs users between 1996 and 2011. ConClusions: We found evidence that the 
use of TCAs was associated with elevated risk of MI. Further research is needed 
to identify the underlying biological mechanisms.
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objeCtives: To examine anticoagulant use and bleeding risk in patients with 
venous thromboembolism (VTE) in the U.S. clinical practice setting. Methods: 
Adult patients with VTE were selected from the MarketScan Commercial and 
Medicare Supplemental Databases between 07/01/2006 and 12/31/2011. Patients 
were required to have at least two outpatient visits with VTE diagnosis within 3 
weeks of each other or one inpatient VTE diagnosis. Patients were also required 
to have at least 6 months continuous enrollment in the 6 months prior to first 
VTE diagnosis. Cases consisted of VTE patients who experienced a major bleeding 
event after VTE diagnosis. Control patients were those who did not experience any 
bleed after VTE diagnosis and were 1:1 matched with cases by propensity score. 
Anticoagulant use was categorized as current use (within 2 weeks prior to bleeding), 
past use (more than 2 weeks prior to bleeding), and never used prior to bleeding or 
during follow-up period. Multivariate logistic regression was performed to examine 
the association between anticoagulant use and major bleeding. Results: A total of 
4166 bleeding cases and matched controls were included in the analysis. Compared 
to controls, cases were more likely to currently use anticoagulants (25.6% vs. 16.7%, p 
< .0001). Multivariate logistic regression showed that use of warfarin (past: OR= 1.25; 
current: OR= 1.48), parenteral anticoagulant (past: OR= 1.91; current: OR= 4.59), and 
parenteral anticoagulant plus warfarin (past: OR= 1.36; current: OR= 1.87) were sig-
nificantly associated with increased risk for major bleeding (p< 0.001), after adjusting 
for demographic and clinical factors. Results were similar with sensitivity analysis 
using 1:1 hard matched data on age, sex, type of VTE, and index VTE diagnosis 
date. ConClusions: In patients with VTE, current and past use of anticoagulants 
was associated with increased risk of major bleeding. Study results suggest more 
effective anticoagulants demonstrating lower bleeding risk are needed to treat and 
prevent recurrence of VTE.
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objeCtives: Dronedarone is a non-iodinated benzofuran derivative approved by 
FDA in July 2009. It is used for the treatment of abnormal heart rhythm in patients 
with a history of atrial fibrillation or atrial flutter. The recent evidence suggests there 
is a potential risk of serious cardiovascular adverse events associated with the use 
of dronedarone, especially among patients with permanent atrial fibrillation. The 
objective is to assess the association between use of dronedarone and the risk of 
serious cardiovascular adverse events and other health outcomes. Methods: A 
literature search of peer-reviewed publications relevant to the study was performed 
using PubMed® from 1996 to 2013. Eight clinical trials with a total of 10,800 patients 
enrolled were identified for this study. A meta-analysis of randomized controlled 
trials comparing patients with or without dronedarone was conducted. The drone-
darone group included patients who took dronedarone, and patients who took 
placebo (7 studies) or amiodarone (1 study) were considered as the control group. 
Outcomes included all-cause mortality, cardiovascular mortality and heart failure 
exacerbation. Review Manager 5.2 was used for data analysis. Results: Compared 
to the control group, the use of dronedarone did not significantly increase the risks 
of all-cause mortality (Risk Ratio [RR], 1.27; 95% Confidence interval [CI], 0.80 to 
2.02), cardiovascular mortality (RR, 1.31; 95% CI, 0.53 to 3.24) and heart failure exac-
erbations (RR, 1.19; 95% CI, 0.88 to 1.62). However, after conducting the sensitivity 
analysis which excluded the ATHENA study (the FDA approval of dronedarone was 
based on this trial), we found dronedarone was statistically significant in increasing 
the risk of all-cause mortality (RR, 1.70; CI, 1.13 to 2.56), cardiovascular mortality (RR, 
2.13; 95% CI, 1.10 to 4.15) and heart failure exacerbations (RR, 1.42; 95% CI, 1.07 to 
1.89). ConClusions: The health care professionals should prescribe dronedarone 
cautiously for patients with cardiovascular risk factors.
CArdioVAsCulAr disorders – Cost studies
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objeCtives: To develop a model for estimating reductions in the number of events 
and costs of myocardial infarction (MI) and ischemic stroke (IS) for a US health 
plan as a result of implementing routine testing with multi-tiered cardiovascular 
risk markers of vascular inflammation including hsCRP, Lp-PLA2 and myeloper-
oxidase. Methods: An Excel model was developed to estimate reductions in MI 
and IS as well as reductions in the per-member-per-month (PMPM) and five-year 
costs before testing costs due to biomarker-based testing for a hypothetical US 
health plan. Inputs for the model included: incidence rates of MI and IS, direct costs 
associated with MI and IS, lab results of multi-marker testing, graded risk ratios of 
MI and IS based on combinations of abnormal risk markers, patient monitoring 
and intervention costs, and preventative pharmacotherapy. Preventative pharma-
cotherapy use and costs were based on an analysis of pharmacy claims data. Costs 
savings (2012 USD) were assessed for patients undergoing multi-marker testing 
as compared to patients with lipid panel testing only. Clinical expertise was relied 
upon for inputs relating to treatment response and changes in preventative phar-
macotherapy. Direct costs, incidence rates, and risk ratios were obtained from litera-
ture. Results: For a health plan with 1,000,000 members, an estimated 21,104 MI 
and 22,589 IS events would occur over five years. Implementing this multi-tiered risk 
assessment of inflammatory biomarkers for patients ≥ 35 years old would reduce 
MI and IS events by 2,018 and 1,848, respectively, yielding almost $180.6m in cost 
savings ($3.01 PMPM). Results were sensitive to changes in treatment response. 
Nonetheless, cost savings were observed for most scenarios. ConClusions: This 
study suggests that health plans can realize substantial cost savings by prevent-
ing MI and IS events after implementing routine biomarker testing. Cost savings 
before testing costs could reach more than $3.01 PMPM for a typical US health plan.
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objeCtives: Percutaneous Coronary Intervention (PCI) is used to treat Acute 
Coronary Syndrome (ACS). Currently ACCF/AHA/SCAI PCI guidelines recommend 
use of antithrombin agents (bivalirudin or heparin) in combination with antiplatelet 
agents (oral P2Y12 inhibitors and/or GPIIb/IIIa inhibitors). Bivalirudin has demon-
strated reduced bleeding events vs. heparin+GPI; though, GPI use has declined over 
the past 10 years. Cangrelor, a novel, rapid on/off-set IV P2Y12, reduced ischemic 
events vs. clopidogrel in the CHAMPION program. The aim of our analysis was to 
quantify the impact of using cangrelor and bivalirudin together in PCI from a US 
hospital perspective. Methods: A decision analytic model based on current clinical 
practice was developed to estimate the annual impact of using heparin+/-GPI+/-
clopidogrel (base case) vs. bivalirudin+cangrelor+bailout GPI (scenario). We used 
data from RCTs to estimate event rates (mortality, myocardial infraction, stent 
thrombosis, ischemia-driven revascularization, and major/minor bleeding). Patient 
and GPI mix was derived from an analysis of Premier’s Perspectives Database. GPI 
use in cangrelor patients was based on the CHAMPION Phoenix study. Event costs 
were obtained from published literature and inflation-adjusted to 2013 dollars. 
Drug costs were based on 2013 wholesale acquisition costs. To estimate the clinical 
value of using bivalirudin+cangrelor, we set their costs to $0. Results: For a hypo-
